AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.91 |
Market Cap | 746.38M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.87 |
PE Ratio (ttm) | -2.3 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.01 |
Volume | 1,843,025 |
Avg. Volume (20D) | 1,885,577 |
Open | 2.05 |
Previous Close | 2.06 |
Day's Range | 1.93 - 2.05 |
52-Week Range | 1.21 - 3.04 |
Beta | undefined |
About LAB
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immu...
Analyst Forecast
According to 2 analyst ratings, the average rating for LAB stock is "Buy." The 12-month stock price forecast is $2.88, which is an increase of 43.64% from the latest price.
Next Earnings Release
Analysts project revenue of $47.03M, reflecting a 66.84% YoY growth and earnings per share of -0.08, making a -68.00% decrease YoY.